Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Cognitive Symptoms in Schizophrenia
IRCT20211219053452N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine in schizophrenia, sponsored by Arak University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
atomoxetine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20211219053452N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211219053452N1.